Nanomedicine Market to Remain Competitive | Major Giants Continuously Expanding Market The Manomet Current – The Manomet Current

Global Nanomedicine Market is valued at approximately USD 160 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 12.6% over the forecast period 2020-2027. Nanomedicine is one of the most significant applications of nanotechnology used in the treatment, diagnosis, control, and monitoring of biological systems. Nanomedicine utilizes nanoscale manipulation of materials to enhance medicine delivery. Thus, nanomedicine has enabled the treatment alongside various diseases, such as cancer, cardiovascular diseases, and so on. Nanomedicine is the most promising mode of treatment of cancer. This expanding field of medical research can be utilized to discover improved personalized treatment for cancer in the present scenario. With the benefit of the properties of issue at nanoscale, nanomedicine pledges to create innovative drugs with larger efficacy and reduced side-effects than regular therapies. Thus, the surge in prevalence of cancer may act as a major driving factor for the growth of the market all over the world.

According to the National Cancer Institute (NIH), the prevalence of cancer has a major impact on society in the world and across the United States. As of January 2019, around 16.9 million cancer survivors were reported in the United States and is projected to increase to almost 22.2 million by the year 2030. Also, in 2020, an estimated 1,806,590 new cases of cancer were found and will be diagnosed in the United States. Furthermore, the rise in government approvals for the products developed by the manufacturers, along with the increased emergence of newer technologies for drug delivery are the few factors responsible for the high CAGR of the market during the forecast period. For instance, in February 2017, the Celgene International Srl granted approval for its REVLIMID (lenalidomide) from the European Commission, as monotherapy for patients treatment with multiple myeloma. This, in turn, is expected to strengthen the market growth all over the world. However, the high cost of nanomedicine, coupled with strict government norms for product approval are the few major factors inhibiting the market growth over the forecast period of 2020-2027.

Request for a FREE sample of this market research report@ https://www.reportocean.com/industry-verticals/sample-request?report_id=bw2007

The regional analysis of the global Nanomedicine market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rise in government funding for the nanoscale technology and nanomedicine, and the presence of a significant number of market vendors in the region. Whereas Asia-Pacific is anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as the rise in prevalence of chronic diseases such as cancer, along with the increasing number of venture capital investors in developing countries, such as China and India, would create lucrative growth prospects for the Nanomedicine market across the Asia-Pacific region.

Major market player included in this report are:Abbott LaboratoriesCombiMatrix Corp.General ElectricJohnson & JohnsonMallinckrodt PharmaceuticalsMerck & Co., Inc.Luminex CorporationPfizer Inc.Leadiant Biosciences, Inc.Teva Pharmaceutical Industries Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Modality:DiagnosticsTreatments

By Application:Drug DeliveryVaccinesDiagnostic ImagingRegenerative MedicineImplantsOthers

By Indication:Oncological DiseasesInfectious DiseasesCardiovascular DiseasesOrthopedic DisordersNeurological DiseasesOthers

By Region:North AmericaU.S.CanadaEuropeUKGermanyFranceSpainItalyROE

Asia PacificChinaIndiaJapanAustraliaSouth KoreaRoAPACLatin AmericaBrazilMexicoRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018Base year 2019Forecast period 2020 to 2027

Send a request to Report Ocean to understand the structure of the complete report @https://www.reportocean.com/industry-verticals/sample-request?report_id=bw2007

Target Audience of the Global Nanomedicine Market in Market Study:

Key Consulting Companies & AdvisorsLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Resellers (VARs)Third-party knowledge providersInvestment bankersInvestors

See the original post:
Nanomedicine Market to Remain Competitive | Major Giants Continuously Expanding Market The Manomet Current - The Manomet Current

3d Cell Culture Market: How Leading Companies Respond to New Market Drivers by Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix,…

Detailed research added by Adroit Market Research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the 3d Cell Culture market in the latest research report. The research study concisely dissects the 3d Cell Culture and unearths valuable estimations pertaining to the profit projections; market size, sales capacity, and numerous other crucial parameters. Also, the 3d Cell Culture Market report appraises the industry fragments as well as the driving factors impacting the remuneration scale of this industry.

Procure Sample Report + All Related Table and Graphs @https://www.adroitmarketresearch.com/contacts/request-sample/593

For more data or any query mail at[emailprotected]

Competition landscape

-Business Strategies of Leading and prominent market players in 3d Cell Culture.

-Product offering and development analysis.

-Market share & positioning analysis.

-SWOT analysis of the prominent market players.

-Industry-wide business strategies and trends.

Competitive Landscape Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix, Dickinson and Company

The 3d Cell Culture Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.

Market Analysis by Applications:By Application,(Regenerative medicine,Drug discovery,Stem cell research,Cancer research)

Market Analysis by Type:By End-User, (Academic institutes,Contract research laboratories,Pharmaceutical & biotechnology companies), By Product Type, (Services,Microchips,Bioreactors,Gels,Scaffold-based platforms,Scaffold-free platforms,Solid scaffolds,Nano-porous scaffolds,Micro-porous scaffolds,Macro-porous scaffolds)

1. Which end-user is likely to play a crucial role in the development of the 3d Cell Culture market?

2. Which regional market is expected to dominate the 3d Cell Culture market in 2020?

3. How are consumer trends impacting the operations of market players in the current scenario of the 3d Cell Culture market?

4. Why are market players eyeing opportunities in region 1?

5. What are the growth prospects of the 3d Cell Culture market in region 1 and region 2?

6. What impact does COVID-19 have made on 3d Cell Culture Market Growth & Sizing?

(1) The information presented in the report helps your decision-makers to become prudent and make the best business choices.

(2) The report enables you to see the future of the 3d Cell Culture market and accordingly take decisions that will be in the best interest of your business.

(3) It offers you a forward-looking perspective of the 3d Cell Culture market drivers and how you can secure significant market gains in the near future.

(4) It provides a SWOT analysis of the 3d Cell Culture market along with useful graphics and detailed statistics providing quick information about the markets overall progress throughout the forecast period.

(5) It also assesses the changing competitive dynamics of the 3d Cell Culture market using pin-point evaluation.

6. Impact Analysis of COVID-19 on 3d Cell Culture Market

To conclude, the 3d Cell Culture Market report will provide the clients with a high-yielding market analysis assisting them to understand the market status and come up with new market avenues to capture hold of the market share.

If you have any special requirements, please let us know and we will offer you the report at customized price.

Chapter 1 Market Overview

Chapter 2 Industry Chain

Chapter 3 Environmental Analysis

Chapter 4 Market Segmentation by Type

Chapter 5 Market Segmentation by Application

Chapter 6 Market Segmentation by Region

Chapter 7 Market Competitive

Chapter 8 Major Vendors

Chapter 9 Conclusion

About Us

Contact Us:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Original post:
3d Cell Culture Market: How Leading Companies Respond to New Market Drivers by Thermo Fisher Scientific, Nanofiber Solutions, Advanced Biomatrix,...

Kanazawa University research: The Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University is organizing the 4th NanoLSI Symposium on 26 and…

KANAZAWA, Japan, Nov. 17, 2020 /PRNewswire/ --The 4th NanoLSI Symposium will be a virtual meeting covering bio-imaging, sensing, and manipulation for medical science. The Nano Life Science Institute (WPI-NanoLSI) was established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology.

Symposium website

https://nanolsi.kanazawa-u.ac.jp/en/4th-sympo/

Flyer

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2020/11/NanoLSI_symposium_2020.jpg

Program details

https://nanolsi.kanazawa-u.ac.jp/wp-content/uploads/2020/11/program.pdf

Nano Life Science Institute (WPI-NanoLSI) aims to acquire a fundamental understanding of various life phenomena, such as development, disease, and aging at the nano-level through transdisciplinary research of Nanometrology, Life Science, Supramolecular Chemistry, and Computational Science.

To further develop interdisciplinary research, the WPI-NanoLSI has organized annual international symposia to build new collaborative relationships with researchers across the world.

This year's fourth symposium will be held online because of restrictions to travel due to the COVID-19 pandemic. To facilitate research exchange that is only possible through online, the WPI-NanoLSI has invited prominent researchers from Europe, North America, and Asia to give talks during the symposium, where each session is scheduled according to the local times of the speakers.

This is an excellent opportunity to gain valuable insights into the latest research findings in bio-imaging, sensing, and manipulation for medical science.

Details

Date: 26 -27 November 2020

Format: Virtual conference (via Zoom) that is free of charge

Timetable

Thursday 26 November

07:40 07:50 (JST) Opening remarks

08:00 10:00 (JST) 1st session

Molecular and cellular dynamics in biological regulation and regenerative medicine

Chair: Prof. Kunio MATSUMOTO/ NanoLSI/CRI

Speakers: Prof. Simon SCHEURING/ Weill Cornell Medicine

Assoc. Prof. Yusuke MIYANARI/ NanoLSI/CRI

Prof. Kenneth S. Zaret/ University of Pennsylvania

Prof. Takanori TAKEBE/ Tokyo Medical and Dental University

10:00 11:00 (JST). Virtual poster session

*Need Separate registration. Please see website

13:30 15:30 (JST) 2nd session

Chemistry-Driven Challenges: from Molecule to Nano/Microscale

Chair: Assoc.Prof. Satoshi ARAI/ NanoLSI

Speakers: Prof. Tomoki OGOSHI/ Kyoto University

Assoc. Prof. Toshinori FUJIE/ Tokyo Institute of Technology

Assoc. Prof. Etsuo SUSAKI/ The University of Tokyo

Prof. Susumu KITAGAWA/ Kyoto University

15:30 16:00 (JST) Video session #1

17:00 19:00 (JST) 3rd session

Nano-scale approaches to physiological and pathological phenomena

Chair: Prof. Toshio ANDO/ NanoLSI

Speakers: Dr. Nobuo NODA/ Institute of Microbial Chemistry

Prof. Noriyuki KODERA/ NanoLSI

Assoc. Prof. Shinji WATANABE/ NanoLSI

Prof. Victor SHAHIN/ University of Mnster

19:00 19:30 (JST) Video session #2

Friday 27 November

10:00 12:00 (JST) 4th session

Imaging approaches to explore cancer biology

Chair: Prof. Masanobu OSHIMA/ NanoLSI/CRI

Speakers: Asst. Prof. Keehoon JUNG/Seoul National University College of Medicine

Prof. Takeshi IMAMURA/ Ehime University

Asst. Prof. Ann-Marie CHACKO/ Duke-NUS Medical School

Prof. Masanobu OSHIMA/ NanoLSI/CRI

12:00 12:05 (JST) Closing remarks

Further information

About WPI nanoLSI Kanazawa University Hiroe YonedaVice Director of Public AffairsWPI Nano Life Science Institute (WPI-NanoLSI)Kanazawa UniversityKakuma-machi, Kanazawa 920-1192, JapanEmail: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81 (76) 234-4550

About Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

SOURCE Kanazawa University

See original here:
Kanazawa University research: The Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University is organizing the 4th NanoLSI Symposium on 26 and...

Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) – TechnoWeekly

The global Healthcare Nanotechnology (Nanomedicine) Market study offers a compilation of the current, historical, and future outlook of the industry as well as the factors responsible for market growth. With a SWOT analysis, the business study highlights the weaknesses, strengths, opportunities, and threats of each Healthcare Nanotechnology (Nanomedicine) Market player in a comprehensive way.

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-64780?utm_source=SA/technoweekly

Under the COVID-19 outbreak analysis, this report provides analysis of import, supply chain, and export to future influence on the industry and regional government policies. Enterprise competition pattern, detailed analysis about market status, advantages and disadvantages of enterprise products, macroeconomic policies and regional industrial layout characteristics, industry development trends have also been included. The trends of product sales channel will be offered as well.

Considering COVID-19, this report offers a complete and exhaustive analysis on how the epidemic has pushed transformation and reform in the industry. The market study can help understand the market expansion and strategies for business accordingly. In the strategy analysis, it gives insights from market positioning marketing channel to potential growth strategies, thereby providing an in-depth analysis for new entrants or existing competitors in the Healthcare Nanotechnology (Nanomedicine) industry.

Key Players: Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd..

The market analysis on the Healthcare Nanotechnology (Nanomedicine) offers a birds eye view of the current proceeding within the Healthcare Nanotechnology (Nanomedicine) Market. The market analysis report has incorporated an analysis of various factors that augment the markets growth. It constitutes restraints, trends, and drivers that transform the market in either a negative orpositive manner.

Healthcare Nanotechnology (Nanomedicine) Market

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-64780?utm_source=SA/technoweekly

This market analysis also offers the scope of different segments and applications that can actually impact the market in the future. The thorough information is based on present trends and historic milestones. The market analysis mentions the volume of sales by region from 2015 to 2026. A thorough evaluation of the limitations included in the market analysis portrays the drivers and gives room for strategic planning.

Global Healthcare Nanotechnology (Nanomedicine) Market: Segment Analysis

Each type offers information about return sover the forecast period of 2018 to 2028. The sales method segment also offers revenue by volume and sales over the forecast period of 2018 to 2028. Understanding the segments helps in classifying the importance of various factors that support market growth.

Following are the segmentation covered by the market study: By Application (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), By Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases and Other Diseases)

Global Healthcare Nanotechnology (Nanomedicine) Market: Regional Analysis

The market analysis report includes a thorough study of various factors that determine regional growth such as environmental, economic, social political status, technology, and region. Market analysis has studied the data of sales, revenue, and manufacturers of each region. The market analysis provides region-wise volume and revenue for the forecast period of 2016 to 2028. This market analysis will support the market participants to understand the potential worth of investment in a particular region.

Region- wise Analysis of the Global Healthcare Nanotechnology (Nanomedicine) Market covers: North America Europe Asia Pacific Middle East and Africa South America

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-64780?utm_source=SA/AF

Global Healthcare Nanotechnology (Nanomedicine) Market: Competitive Landscape

This market analysis report classifies numerous key manufacturers of the industry. It supports the reader in understanding the policies and collaborations that the industry participants are focusing on in order to combat competition in the industry. The comprehensive market analysis offers a note worthy microscopic look at the industry. The market analysis can classify the footprints of the manufacturers by giving the global revenue of manufacturers and sales by manufacturers, and the global price of manufacturers over the forecast period of 2018 to 2028.

Major Aspects covered in the Report are

Further, the report provides niche insights for a decision about every possible segment, helping in the strategic decision-making process and market size estimation of the Healthcare Nanotechnology (Nanomedicine) Market on a regional and global basis. Unique research designed for market size estimation and forecast is used for the identification of major companies operating in the market with related developments. The report has an exhaustive scope to cover all the possible segments, helping every stakeholder in the Healthcare Nanotechnology (Nanomedicine) Market.

Reasons for buying this report:

Why Do Companies Trust QMI?

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Excerpt from:
Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) - TechnoWeekly

Nordic Nanovector ASA: Results for the Third Quarter 2020 – BioSpace

OSLO, Norway, Nov. 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management team will take place today in Oslo at 08.30 CET, see details below. A link to the webcast and the presentation is available from the company's homepage (www.nordicnanovector.com).

Lars Nieba, Interim CEO of Nordic Nanovector, said: "Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. Generating these data will require us to successfully navigate the latest challenges of increased COVID-19 restrictions. We remain confident in our ability to achieve this goal, aided by the protocol amendments, the possibility to reduce the patient sample, and all the other measures we are actively implementing to drive patient recruitment into PARADIGME."

Q3'2020 Highlights

Events after Q3'2020

Financial Highlights

(Figures in brackets = same period 2019 unless otherwise stated)

Outlook

The company continues to target the readout of three-month top line data from PARADIGME in H2'2021. Approval of protocol amendments is proceeding as planned and completed in the best-recruiting countries, and other initiatives to increase the rate of enrolment are underway. The company also targets the readout of three-month top line data from the second cohort of the Archer-1 trial in H1'2021.

However, the impact of the COVID-19 pandemic on patient recruitment has worsened in light of the emergence of a second wave resulting in severe travel restrictions being implemented in the various countries where we are executing our clinical studies. These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. Several proactive actions have been taken to minimize the impact of these travel restrictions which could blunt further delays in completing enrolment and delivering preliminary results as targeted.

The company has taken steps to conserve cash and following the recent successful private placement, Nordic Nanovector has a cash runway that extends into Q3'2021.

Despite the challenging times, the many positive actions the company has made in the last nine months have improved the prospects of delivering pivotal results from PARADIGME in H2'2021.

The company continues to believe that, if positive, these trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin as a highly promising new targeted therapy that can address the unmet needs of R/R FL patients.

Presentation and live webcast Q3 2020 results

A presentation and live webcast by Nordic Nanovector's management team will take place today at 8:30 am CET.

The webcast can be accessed from http://www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation is available at http://www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Further information can be found at http://www.nordicnanovector.com .

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--results-for-the-third-quarter-2020,c3239830

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-results-for-the-third-quarter-2020-301176750.html

SOURCE Nordic Nanovector

Company Codes: Bloomberg:NANO@NO, ISIN:NO0010597883, Oslo:NANO, RICS:NANO.OL

Visit link:
Nordic Nanovector ASA: Results for the Third Quarter 2020 - BioSpace

SHAREHOLDER ALERT: WeissLaw LLP Reminds WTRE, TOTA, HCAC, and OAC Shareholders About Its Ongoing Investigations – PRNewswire

NEW YORK, Nov. 16, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212)682-3025(888) 593-4771[emailprotected]

Watford Holdings Ltd. (NASDAQ: WTRE)

WeissLaw LLPis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Watford Holdings Ltd. (NASDAQ: WTRE) in connection withthe proposed acquisition of the company by Arch Capital Group Ltd. ("ACGL"). Under the terms of the acquisition agreement, WTRE shareholders will be entitled to receive $31.10 in cash for each share of WTRE common stock that they own. If you own WTRE shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/wtre/

Tottenham Acquisition I Limited (NASDAQ: TOTA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors ofTottenham Acquisition I Limited (NASDAQ: TOTA) in connection with the company's proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. ("Clene"). Under the terms of the merger agreement, TOTA will acquire Clene through a reverse merger that will result in Clene becoming a public company listed on the Nasdaq Capital Market. The proposed transaction values Clene at $542.5 million. If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tottenham-acquisition-i-limited/

Hennessy Capital Acquisition Corp. IV(NASDAQ: HCAC)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hennessy Capital Acquisition Corp. IV(NASDAQ: HCAC)in connection with HCAC's merger with privately-held Canoo Holdings Ltd. ("Canoo"). Under the terms of the proposed transaction, HCAC will acquire Canoo through a reverse merger that will result in Canoo becoming a publicly-listed company. If you own HCAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/hennessy-capital-acquisition-corp-iv/

Oaktree Acquisition Corp. (NYSE: OAC)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oaktree Acquisition Corp. (NYSE: OAC) in connection with the company's proposed merger with privately-held telehealth company Hims, Inc. ("Hims"). Under the terms of the merger agreement, OAC will acquire Hims through a reverse merger that will result in Hims becoming a publicly-listed company on the New York Stock Exchange under the new ticker symbol "HIMS." If you own OAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/oac/

SOURCE WeissLaw LLP

http://weisslawllp.com

Originally posted here:
SHAREHOLDER ALERT: WeissLaw LLP Reminds WTRE, TOTA, HCAC, and OAC Shareholders About Its Ongoing Investigations - PRNewswire

Messenger RNA the Therapy of the Future – Newswise

With two companies leading the way in development of an mRNA (messenger RNA) vaccine to ward off COVID-19, one Houston Methodist physician researcher sees it as the first step for what has the potential to become the therapy of the future for all types of diseases. John Cooke, MD, PhD, director of the Research Institutes RNA therapeutics program, says mRNA is basically writing biological code to tell our bodies what proteins to make. Scientists need only the genomic sequence of the virus to come up with strategies to intervene.

Most vaccines today are still viral vaccines they are inactivated virus, so its potentially infectious and you have to have virus on hand, Cooke said. With mRNA, youre just writing code which is going to tell the cell to make a viral protein one part of a viral protein to stimulate an immune response. And, heres the wonderful thing, you dont even need the virusin hand, just its DNA code. His team is working with Houston Methodists nanomedicine team to develop better delivery options for mRNA, and he sees its potential in many fields: cancer, cardiovascular disease, liver disease, other infectious diseases and even rejuvenation.

Dr. John Cooke is available for interviews to discuss the process and promise of mRNA technology.

More:
Messenger RNA the Therapy of the Future - Newswise

Antibacterial Properties of OsteoFab PEKK Implants Defined in New Research, Outperforming PEEK and Titanium – PR Web

We have been continually impressed with the strong bacteria resistance and pro-bone cell responses of OPMs PEKK samples, said Dr. Thomas Webster of Northeastern University. All resulting from optimal surface properties without resorting to the use of antibiotics or the release of growth factors

SOUTH WINDSOR, Conn. (PRWEB) November 18, 2020

Oxford Performance Materials, Inc. (OPM), an industry leader in advanced materials science and high performance additive manufacturing (HPAM), today announced additional results of an ongoing scientific study analyzing the antibacterial properties of 3D printed PEKK (poly-ether-ketone-ketone). These new results definitively establish a mechanism of action for how 3D printed PEKK exhibits inherent antibacterial characteristics, further confirming PEKKs role in combatting implant infections. In a continued partnership with Dr. Thomas Webster of Northeastern University, this research builds upon a September 2017 study(1) where samples produced by OPMs proprietary OsteoFab process demonstrated for the first time the promise that nanostructured PEKK has for numerous anti-infection orthopedic implant applications.

In a second set of experiments conducted by Dr. Webster in December 2019, it was determined that 3D printed PEKK demonstrated significant reductions for all bacteria colonization(2) when measured via colony forming units, crystal violet staining, and live/dead assays. This was true for all tested bacteria strains, which included S. epidermidis, P. aeruginosa, and MRSA, and all tested materials, as 3D printed PEKK significantly outperformed commercially available titanium and PEEK controls. This study was important for two primary reasons: it confirmed the results seen in the 2017 study(1) in the presence of titanium and PEEK controls and it raised the question of why PEKK is superior in this aspect, hinting that 3D printed PEKK may have a biologically optimal surface energy in the context of bacterial aversion.

In April of 2020, a follow-up study was conducted to determine the mechanisms of the antibacterial properties of 3D printed PEKK after 24 hours of culture, specifically examining protein adsorption and correlating that adsorption to bacteria response. Based on the test results(2), 3D printed PEKK exhibited a surface energy (35.7 mN/m) that was much closer to proteins lubricin (40 mN/m), mucin (42-46 mN/m), and casein (48 mN/m), which are all proteins known to reduce bacteria attachment and colonization naturally in vivo. When compared to the surface energies of PEEK (16.3 mN/m) and titanium (62.5 mN/m), it was evident 3D printed PEKK is optimal in terms of similarity to these naturally occurring proteins. As expected, the experiment showed greater protein adsorption of lubricin, mucin, and casein on PEKK in comparison to PEEK and titanium controls.

This greater protein adsorption was then correlated to greater bacteria inhibition of 3D printed PEKK compared to commercially available PEEK and titanium. For this portion of the study, samples were coated with lubricin, mucin, and casein, and bacteria attachment was characterized using colony forming unit counts, crystal violet staining, and live/dead assays. All results correlated the increased protein adsorption to decreased bacteria colonization for S. epidermidis, P. aeruginosa, and MRSA, again compared to PEEK and titanium controls.

This finding is extremely important as it provides objective evidence explaining why OPMs 3D printed PEKK exhibits inherent antibacterial effects. We have been continually impressed with the strong bacteria resistance and pro-bone cell responses of OPMs PEKK samples, said Dr. Webster. All resulting from optimal surface properties without resorting to the use of antibiotics or the release of growth factors, as our studies have shown. Equally significant are the implications of lubricin adsorption onto 3D printed PEKK, in terms of future joint and cartilage applications of the OsteoFab technology platform. Lubricin is a naturally occurring protein that is secreted in synovial joints; it coats surrounding cartilage and contributes to the overall integrity of the joint. With demonstrated adhesion to 3D printed PEKK, new devices could provide even more benefits in an increasing number of orthopedic applications.

The antibacterial attributes of 3D printed PEKK are significant since they address a key area of growing concern in medicine orthopedic implant infections. 3D printed PEKKs antibacterial properties, as detailed in this new study, will provide another important layer of differentiation for the performance of OsteoFab medical devices in the marketplace. Results from these experiments will be available in a forthcoming publication.

About Oxford Performance Materials, Inc.

Oxford Performance Materials, Inc. was founded in 2000 to exploit and commercialize the worlds highest performing thermoplastic, PEKK (poly-ether-ketone-ketone). OPMs Materials business has developed a range of proprietary, patented technologies for the synthesis and modification of a range of PAEK polymers that are sold under its OXPEKK brand for biomedical and industrial applications. The Company is a pioneer in 3D printing. OPM Biomedicals OsteoFab technology is in commercial production in numerous orthopedic implant applications, including cranial, facial, spinal, and sports medicine devices. OPM is the first and only company to receive FDA 510(k) clearance to manufacture 3D printed, patient-specific polymeric implants, and the company has six 510(k) clearances in its portfolio. OPM Industrial produces 3D printed OXFAB production parts for highly demanding applications in the energy, transportation, and semiconductor markets. OXFAB structures offer significant weight, cost, and time-to-market reductions that are defined in a set of specified performance attributes in the exhaustive OPM B-Basis database, developed in conjunction with NASA. For more information, please visit: http://www.oxfordpm.com

References

Antibacterial Properties of PEKK for Orthopedic Applications, International Journal of Nanomedicine, Dovepress 15-Sep-2017, Mian Wang, Garima Bhardwaj (Department of Chemical Engineering, Northeastern University, Boston MA) and Thomas J. Webster (Department of Chemical Engineering, Northeastern University, Boston MA and Wenzhou Institute of Biomaterials and Engineering, Wenzhou Medical University, Wenzhou, China). The full study by Mian Wang, et al. may be viewed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592909/

2. https://oxfordpm.com/uploads/files/OPM-T._Webster_AM_Med_Summit_19Oct2020_website.pdf?v=1605303394194

Company Contact: Bernie Plishtin Oxford Performance Materials 860-656-9446 bplishtin@oxfordpm.com

Share article on social media or email:

Originally posted here:
Antibacterial Properties of OsteoFab PEKK Implants Defined in New Research, Outperforming PEEK and Titanium - PR Web

Nanomedicine Market: Clear Understanding of The Competitive Landscape and Key Product Segments – PRnews Leader

Overview:

Nanomedicineis an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.

Click Here to Get Sample Premium Report @https://www.trendsmarketresearch.com/report/sample/9807

Majority of nanomedicines prescribedcurrently, allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

Market Analysis:

The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Regional Analysis:

The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis:

Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players:

Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis:

At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits:

The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Continued here:
Nanomedicine Market: Clear Understanding of The Competitive Landscape and Key Product Segments - PRnews Leader

Bio-convergence may be next big thing from Israel – Cleveland Jewish News

Testing new cancer drugs on 3D-printed tumor cells. Analyzing the gut microbiome to determine the best medicine for Crohns disease. Identifying genetic pairs so that a drug can turn off a cancer cell.

These are just a few of the overlaps of biology, physics, computer science, mathematics, engineering, materials science and nanotechnology that make up the new field of bio-convergence.

Testing new cancer drugs on 3D-printed tumor cells. Analyzing the gut microbiome to determine the best medicine for Crohns disease. Identifying genetic pairs so that a drug can turn off a cancer cell.

These are just a few of the overlaps of biology, physics, computer science, mathematics, engineering, materials science and nanotechnology that make up the new field of bio-convergence.

The Israel Innovation Authority is betting on bio-convergence as the next big thing from the startup nation.

The IIA announced in January that it would invest up to about $30 million in bio-convergence technologies and companies. In July, the governmental agency added a call for R&D proposals from academia and industry in the field of bio-convergence with a budget of $4 million.

In August, a third call for bio-convergence proposals this time for collaboration between Israeli and South Korean companies came with a $4.16 million budget and a plan to provide grants up to 50 percent of R&D expenses.

The bio-convergence push is a bit of a departure for the IIA.

We usually work in a bottom up approach and very seldom intervene and select a specific technological field for strategic investments, Anya Eldan, vice president of the IIAs Startup Division, said. In the past it has been cyber and fintech. Now weve identified bio-convergence as the next growth engine for the Israeli economy.

Developing disease-fighting drugs the old-fashioned way takes decades and billions of dollars. The new era of pharma will see researchers from multiple disciplines working together.

When we started to look for the next growth engine, we realized that none of the major pharmaceutical companies are invested in bio-convergence, Eldan explained. Theyre looking at biology but theyre not sure how to approach it.

Israel, however, is a small country where everyone knows one another, making it relatively easy to put together multidisciplinary teams.

On a folksier level, Eldan said Israelis large Friday night Shabbat dinners naturally foster collaboration.

People have to find things to talk about. So, a doctor mentions at the dinner table he has a patient without a solution and the engineer in the family says, That shouldnt be, and from there a startup is born.

This trend could have a major impact on the global health care system crisis. Health expenditures worldwide were expected to reach $10 trillion by 2022 even before the advent of COVID-19. Half the U.S. population is considered chronically ill, accounting for some 85% of the total expenditure on healthcare services.

The IIA has identified approximately 80 companies working in the field of bio-convergence. Much of the knowhow is tucked away in Israels academic centers.

Ronit Satchi Fainaro is a prime example.

Named Woman of the Year by the Israeli business publication Globes in 2019, Satchi Fainaro heads the 30-person cancer research and nano-medicine laboratory in the department of physiology and pharmacology at Tel Aviv University.

Satchi Fainaros lab includes research associates in biology, chemistry, medical engineering, bioinformatics and even an architecture student, she said. We are living in the post-genomic era, so theres a lot of room for computer science.

Satchi Fainaros lab developed a method for 3D printing cancerous brain tumors using MRI on images.

We do the image analysis and convert it to a file that a 3D printer can read. Then we create a 3D-printed tumor its like a Mini-Me of that tumor, she said, referring to the Mike Meyers character from the Austin Powers films.

Satchi Fainaros lab creates not one but up to 20 mini-tumors, which are then connected to a set of tubes and pumps that deliver simulated blood and most importantly chemotherapy or other cancer treatments. That allows physicians to test drugs on a perfect copy of the actual tumor.

Satchi Fainaro is also working on an immunotherapy nano-vaccine for melanoma and an immune-modulated response against Covid-19.

Jonathan Solomon and Assaf Oron are the CEO and chief business development officer, respectively, of BiomX, another Israeli bio-convergence pioneer.

BiomX is working on a treatment for Crohns and other inflammatory bowel diseases by sequencing the bacteria in a patients microbiome in order to deliver a gut-punch to the exact bacteria causing symptoms.

BiomXs technology is based on the hypothesis that these diseases are driven by the microbiome and that specific bacteria seem to be pro-inflammatory and antibiotic resistant, Solomon tells ISRAEL21.

Bacteriophage image courtesy of BiomX

Bio-convergence techniques assure that a patient receives the right phages a type of virus that infects bacteria to kill only the offending microbes.

Antibiotics are very indiscriminate killers, Solomon said, which leads to the killing of both harmful and beneficial bacteria and, in many cases, the development of antibiotic-resistant bacteria. Phages are very precise. There are no side effects.

Beyond IBD, acne and liver disease are next on BiomXs list. Even cancer is a possibility.

BiomXs technology was initially developed and licensed from the Weizmann Institute in Rehovot. The company has 100 employees and is publicly traded in the United States.

Then theres Pangea, whose bio-convergence niche is synthetic lethality.

Its a very simple notion with a confusing name, chief technology officer Tuvik Beker said.

The basic idea is that genes often act in pairs. If a gene is acting unnaturally in a tumor (for example, it may be shut down due to mutation or abnormal expression), identifying and shutting down the genes partner can selectively kill the malignant cells.

Pangea brings the computational element.

If there are 20,000 genes in the human genome, simple math means there are about 400 million gene pairs, Beker explained. To test all these pairs for synthetic lethality is very challenging.

As a result, most companies restrict themselves to a couple of hundred genes that they know are important in cancer. Pangea, by contrast, looks for paired genes that are vulnerable to collateral damage, not just the ones driving the tumor, Beker said.

The Tel Aviv-based company hopes to launch its service commercially as early as 2021 with a focus on providing personalized treatment recommendations.

See the original post here:
Bio-convergence may be next big thing from Israel - Cleveland Jewish News

Advanced NanoTherapies Raises $5.3 Million in Seed-Round Financing – Business Wire

LOS GATOS, Calif.--(BUSINESS WIRE)--Advanced NanoTherapies, Inc., a privately-held medical device company committed to exploring nanotechnology for enhanced drug uptake and sustained retention, today announced it has closed on the final tranche of its seed-round financing for a total of $5.3 million as a result of achieving a successful pre-clinical milestone. Funding came from a variety of angel investment sources in the US, Canada, Europe, Asia, and the Middle East, including venture funding from Cleveland Clinic and ForMed Ventures of Taiwan.

Advanced NanoTherapies is led by CEO Marwan Berrada-Sounni, an entrepreneur with extensive experience in percutaneous therapies, including electrophysiology, structural heart, and cardiovascular and endovascular devices.

Our initial focus is on bringing a safer and more effective therapeutic option to patients with peripheral artery disease (PAD) using Sirolimus-coated angioplasty balloons, said Berrada-Sounni. This funding will help us accelerate the development process, build our infrastructure, and move towards bringing this novel technology to patients with PAD.

Advanced NanoTherapies technology platform leverages patented biodegradable functionalized nanoparticles (f-NPs) and a proprietary coating process developed at Cleveland Clinic.

We know that f-NPs enable and improve drug uptake and retention into cells and tissue, said inventor Vinod Labhasetwar, PhD., Professor and Endowed Chair of Nanomedicine, Department of Biomedical Engineering at Cleveland Clinic Lerner Research Institute. Due to technically challenging requirements involved in delivering Sirolimus efficiently to a stenosed artery, Advanced NanoTherapies use of f-NP is an innovative approach.

Advanced NanoTherapies licensed the technology from Cleveland Clinic Innovations.

While drug delivery using coated balloons is a well-established treatment strategy, our vision for using f-NP technology to address PAD represents a major advancement in drug-coated balloon (DCB) technology, said Dr. Mehdi Shishehbor, President, Harrington Heart and Vascular Institute University Hospitals, Cleveland and co-founder and Chief Medical Officer of Advanced NanoTherapies. This technology has implications for many other applications, such as coronary and peripheral in-stent restenosis, below-the-knee tibial disease in CLI, and dialysis AV graft treatment.

Berrada-Sounni added that the company will be working closely with the FDA to achieve an early feasibility study and introduce its technology to human populations.

About Advanced NanoTherapies

Co-founded by Marwan Berrada-Sounni, Advanced NanoTherapies, Inc. is a highly specialized medical device company that is developing a nanoparticle technology-based platform for drug delivery. The company is currently focused on cardiovascular and endovascular applications to bring a safer therapeutic option to patients with PAD using Sirolimus-coated angioplasty balloons. To learn more about Advanced NanoTherapies, visit http://www.AdvNanoT.com.

Go here to read the rest:
Advanced NanoTherapies Raises $5.3 Million in Seed-Round Financing - Business Wire

Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging…

The Healthcare Nanotechnology (Nanomedicine) market report offers a comprehensive and in-detail assessment of the Healthcare Nanotechnology (Nanomedicine) market and focuses on the key growth contributors of the market to gain a knowledgeable insight on the market. The report contains a detailed account of the history of the Healthcare Nanotechnology (Nanomedicine) market and a thorough and detailed forecast up to the year 2026.

The report takes into account the important factors and aspects that are crucial to the client to post good growth and establish themselves in the Healthcare Nanotechnology (Nanomedicine) market. Aspects such as sales, revenue, market size, mergers, acquisitions, risks, demands, new trends, threats, opportunities, and much more are taken into account to procure a detailed and descriptive research report on the Healthcare Nanotechnology (Nanomedicine) market.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/36794

Description:

This report offers segmented data categorized as per related segments of the Healthcare Nanotechnology (Nanomedicine) market and as the international markets change, the report has documented all the essential aspects that affect the overall growth curve of the market. The reports cover all the segments extensively and offer a detailed explanation of all the factors crucial to growth.

The given report has been assessed to give maximum benefit to our clients and to establish them among the frontrunners in the Healthcare Nanotechnology (Nanomedicine) market. The report has been compiled by using various analyses that have proven to be a game-changer for many in the Healthcare Nanotechnology (Nanomedicine) market. The research sources and tools used by our analysts to assess the report are highly reliable and trustworthy and are approved by industry experts.

The following players are covered in this report:

Amgen

Teva Pharmaceuticals

Abbott

UCB

Roche

Celgene

Sanofi

Merck & Co

Biogen

Stryker

Gilead Sciences

Pfizer

3M Company

Johnson & Johnson

SmitH& Nephew

Leadiant Biosciences

Kyowa Hakko Kirin

Takeda

Ipsen

Endo International

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/36794

Competitive Analysis:

The report offers effective guidelines and recommendations for players to secure a position of strength and dominance in the Healthcare Nanotechnology (Nanomedicine) market. The report offers extensive coverage of the competition and has a detailed account of the mergers, acquisitions in the Healthcare Nanotechnology (Nanomedicine) market landscape.

The report includes comprehensive data on mergers and acquisitions that will help the clients to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.

Breakdown Data by Type

Nanomedicine

Nano Medical Devices

Nano Diagnosis

Other

Healthcare Nanotechnology (Nanomedicine) Breakdown Data by Application

Anticancer

CNS Product

Anti-infective

Other

Based on regional and country-level analysis, the Healthcare Nanotechnology (Nanomedicine) market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

Have Any Query ask to our Expert @ https://beathanreports.com/get-expert-help/36794

Reasons to buy:

See more here:
Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging...

MagForce AG: ‘NanoTherm School’ successfully enters the third round with ‘Module B – Part II’ – PharmiWeb.com

DGAP-Media / 20.10.2020 / 09:50

MagForce AG: 'NanoTherm School' successfully enters the third round with 'Module B - Part II'

- MagForce successfully hosted the third session of the practice-oriented, unique and multifaceted application training series for the use of the NanoTherm therapy system for the treatment of glioblastoma.

- The NanoTherm School is part of MagForce's commitment to further optimize the therapy system and train healthcare professionals in its use, and to a broad geographic coverage to increase the availability of the therapy, in order to provide glioblastoma patients with the best care possible.

- The workshop was led by Univ.-Prof. Dr. med. W. Stummer, Director of the Department of Neurosurgery at the University Hospital Mnster

Berlin, October 20, 2020 - With 'Module B - Part II - stereotactic Instillation' MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, conducted the third round of its NanoTherm School.

The application training series was launched in January 2019 to provide the highest quality of treatment through ongoing support for physicians and certify surgeons in the use of the innovative NanoTherm technology. Same as the prior two sessions which took place in January and November 2019, Module B - Part II focused on advanced techniques in the area of stereotactic instillation and the teaching of the NanoPaste procedure.

Another focus was the exchange of information with the individual treatment centers to provide the best possible care for glioblastoma patients. NanoTherm School is part of MagForce's roll-out strategy, which focuses not only on broad geographical coverage to increase the availability of the therapy, but also on its continuous further optimization and the training of healthcare professionals in the use of the therapy system. The training concept of NanoTherm School was developed in close cooperation with Prof. Dr. Walter Stummer, Dr. Michael Schwake from the University Hospital Mnster and PD Dr. Johannes Wlfer from the Hufeland Klinikum GmbH Mhlhausen, who contribute their many years of experience with the NanoTherm therapy system for the treatment of glioblastoma patients.

Among the workshop participants were also representatives of new clinics that focus on the treatment of brain tumor patients, such as Dr. Georgios Naros, M.D., Senior Physician in the Department of Neurosurgery at the University Hospital of Tbingen and Prof. Dr. Angelika Gutenberg, Head of the Neurosurgery Section at Asklepios Klinikum Hamburg - her feedback: "Excellent, hands-on workshop from MagForce. Organization, motivation and high-end equipment cannot be improved!"

Senior Physician MUDr. Vilem Ruzicka, Paracelsus Klinik Zwickau said: "Thank you for a super organized certification course at the NanoTherm Therapy School of MagForce. It was a very successful and, above all, instructive workshop that provides us as medical practitioners with excellent training in the application of new technologies and therapies. This applies in particular to the very practical training of the various instillation methods and the subsequent evaluation of the results. The preparation and execution were very good, and overall it must be said that the set-up in the 'Medicine in the Green' is excellently suited for such workshops."

About NanoTherm School

Targeted towards medical professionals working in the fields of neuro-surgery and neuro-oncology, the 'NanoTherm Therapy School' series aims at introducing participants to the theoretical knowledge and practical techniques required to successfully apply MagForce's NanoTherm technology for the treatment of glioblastoma. In practicing their skills with human specimens, participants are able to familiarize themselves with the procedures and device usages in a stress-free environment under largely real operating conditions.

The 'NanoTherm School' is designed in three consecutive modules allowing participants to gain knowledge and understanding of MagForce's NanoTherm technology starting from basic application techniques (nanopasting) and building to advanced techniques and new surgical application forms in the final module (Module C). The practical section of the course is complemented by lectures on directly relevant aspects of NanoTherm therapy, as well as sample preparation and surgical videos. The equipment and facilities used during the course meet the requirements of today's state-of-the-art surgical equipment.

For more information about NanoTherm School, please contact:Dipl.-Ing. Tobias Hanitsch (thanitsch@magforce.com) Marcel Pilz (mpilz@magforce.com)

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.com.Get to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:Barbara von FrankenbergVice PresidentCommunications & Investor RelationsT +49-30-308380-77E-Mail: bfrankenberg@magforce.com

End of Media Release

20.10.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

More here:
MagForce AG: 'NanoTherm School' successfully enters the third round with 'Module B - Part II' - PharmiWeb.com

Cend Therapeutics Announces Acquisition of Impilo Therapeutics – Yahoo Finance

TipRanks

Is it time for the bears to break out the champagne glasses? Not so fast, says Goldman Sachs. Volatility has ruled the Street for the last few weeks, leading some to conclude that those with a more pessimistic outlook had been vindicated, but the firm believes stocks can still climb higher.According to Goldman Sachs head of U.S. equity strategy, David Kostin, the S&P 500 could still hit 3,600 by the end of the year, and 3,800 by mid-2021, on the back of vaccine-related optimism and progress with the economic reopening. This would reflect gains of 10% and 16%, respectively, should the index ultimately reach these targets.Despite the sharp sell-off in the past week, we remain optimistic about the path of the U.S. equity market in coming months. The Superforecaster probability of a mass-distributed vaccine by Q1 2021 has surged to nearly 70% and economic data show a continuing recovery, Kostin wrote in a recent note. On top of this, the strategist argues the vaccines arrival will push U.S. GDP growth to 6%, compared to the 3.9% consensus estimate.Given Kostins outlook, we wanted to check out three stocks scoring major praise from Goldman Sachs. Not only have they been given a Buy rating, but the firms analysts also see at least 50% upside potential on tap for each. Using TipRanks database, we found out that all three tickers have gotten a thumbs up from analysts at other firms as well. Let's take a closer look.Intellia Therapeutics (NTLA)Focused on utilizing gene editing to develop cell therapies, Intellia Therapeutics wants to stomp out cancer and other immunological diseases for good. Based on its innovative technology, Goldman Sachs recommends that investors pull the trigger.Representing the firm, 5-star analyst Salveen Richter believes that what makes NTLA a stand-out is its use of an adaptive gene editing system based on a proprietary lipid nanoparticle (LNP) delivery method of CRISPR/Cas9 to leverage multiple gene editing strategies. These include the generation of knock-outs (KO) for toxic genes, restoring functional genes by inserting new DNA sequences and the use of consecutive editing combining KO and insertion approaches.We are positive on NTLAs in vivo gene editing approach as it offers a modular system with CRISPR/Cas9 gene editing for functionally curative outcomes. While we note the initial focus is on delivery to the liver, extrahepatic tissue targeting (i.e. CNS) could expand the breadth of NTLAs platform. NTLA is also leveraging its CRISPR/Cas9 editing tools ex vivo to create next-generation engineered cells that can treat oncological and immunological diseases, Richter explained.To this end, the analyst sees several potential catalysts on tap for the next year. Proof-of-concept data for lead program NTLA-2001, its therapy targeting transthyretin amyloidosis (ATTR), a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues, could come by mid-2021. This data stands to inform the drugs clinical profile (safety/tolerability and early signs of sustained TTR knockdown), which would de-risk NTLAs in vivo editing platform, in Richters opinion.On top of this, IND-enabling studies for NTLA-2002, its therapy designed for hereditary angioedema (HAE), and NTLA-5001, its therapy for WT1+ acute myeloid leukemia (AML), are set to kick off in 2021. Richter estimates that peak sales for both candidates could reach $895 million and $806 million, respectively, with data from both also validating the breadth of editing approaches (knockouts and/or insertions).If that wasnt enough, Richter cites the ongoing NVS-led Phase 1/2 OTQ923 sickle cell disease (SCD) trial as a possible upside driver. While we note the limited economics to NTLA from this program and competitor dynamics with bluebird bios (BLUE) LentiGlobin and CRISPR Therapeutics (CRSP) CTX001 that are ahead in clinical development, the study should serve as proof-of-concept for the platform. First data could be presented in 2021, the analyst commented.All of this prompted Richer to initiate coverage with a Buy rating and $33 price target. This target conveys her confidence in NTLAs ability to climb 50% higher in the next year. (To watch Richters track record, click here)Looking at the consensus breakdown, 3 Buys and 2 Holds have been published in the last three months. Therefore, NTLA gets a Moderate Buy consensus rating. Based on the $37.13 average price target, shares could rise 67% in the next year. (See NTLA stock analysis on TipRanks)Vir Biotechnology (VIR)Moving on to another healthcare company, Vir Biotechnology is developing a broad portfolio of product candidates that are designed to combat serious, global infectious diseases in new ways. With it standing at the front of the pack in the COVID-19 monoclonal antibody (mAb) race, its no wonder Goldman Sachs likes what its seeing.Firm analyst Paul Choi cites a recent data readout from one of VIRs competitors as reaffirming his confidence. On September 16, Eli Lilly reported interim data from the Phase 2 BLAZE-1 trial evaluating its mAb therapies, LY-CoV555 and LY-CoV016, in mild or moderate COVID-19 patients. The data revealed that treatment with LY-CoV555 led to a roughly 72% reduction in the need for hospitalization, with no safety signals observed.Choi also points out that the results were more pronounced in high risk patients (age or BMI) as most study hospitalizations across both groups occurred in patients with these underlying risk factors.While resistant viral variants did appear in 8% of LY-CoV555-treated patients and 6% of patients on placebo, management has stated that competing single or multiple mAb cocktail approaches might not be optimized, with viral escape mutants potentially emerging. VIR argues its approach is differentiated given the high barrier to resistance, potent effector function, potential for increased lung tissue concentration and extended half-life.Even though VIR is behind its peers in terms of development timelines, Choi thinks that the company is making substantial progress. VIR recently initiated the Phase 2/3 COMET-ICE study of VIR-7831, its mAb for COVID-19, as a monotherapy (versus a combination approach) in patients with mild or moderate COVID-19. Initial data is set to be released by the end of 2020, with top-line data expected in January. Weighing in on the above, Choi commented, In the absence of preclinical binding affinity data from LY-CoV555, it is premature to hypothesize on the potential for VIR-7831 to demonstrate improved efficacy vs. the competing antibodies; however, we see the LLY data as establishing proof-of-concept for antibodies in COVID-19 while also setting an attainable bar for future antibody monotherapy/cocktail treatments. Moreover, we view the addressable market for COVID-19 antibodies as significant enough to support several approved therapies in the indication in the near-term.In line with his optimistic approach, Choi reiterated his Buy rating and $54 price target. Should the 5-star analysts thesis play out, a twelve-month gain of 69% could potentially be in the cards. (To watch Chois track record, click here)Is the rest of the Street in agreement? The majority of other analysts are. 4 Buys, 1 Hold and 1 Sell have been issued in the last three months, so the word on the Street is that VIR is a Moderate Buy. With the average price target clocking in at $51.67, shares could jump 61% in the next year. (See VIR stock analysis on TipRanks)Peloton Interactive (PTON)Switching gears now, we move on to Peloton Interactive. The company, which offers exercise bikes and remote workout classes, rose to fame at the start of the COVID-19 pandemic. After its fiscal Q4 earnings results blew estimates out of the water, Goldman Sachs believes this stock has more room to run.In the most recent quarter, PTON posted revenue of $607.1 million, beating the $586.2 million consensus estimate and reflecting a 172% year-over-year increase. This is up from growth of 65.6% in the previous quarter. Adjusted EBITDA came in at $143.6 million, ahead of the Streets $73.5 million call. Management pointed to heightened demand during the COVID-19 crisis and significantly lower marketing spend as the drivers of this strong showing.Goldman Sachs Heath Terry tells clients he was especially excited about the Connected Fitness segments performance. Connected Fitness product revenue landed at $486 million, up 199% year-over-year, while customer deposits and deferred revenue grew 300% year-over-year. The five-star analyst also highlights the fact that subscriber net adds were 205,000, versus 174,100 net adds in fiscal Q3 2020 and guidance of 154-164,000.As for PTONs forward-looking guidance, Terry was also impressed. While the company guided fiscal Q1 2021 and FY21 revenue and adjusted EBITDA well above consensus, given the backlog of demand exiting the June quarter and the 6-8 weeks of deliveries already on order by consumers, we expect this guidance will again prove overly conservative, he explained.This performance prompted Terry to state, We continue to believe that Peloton represents a significant long-term opportunity as the company is in the earliest stages of creating new and expanding existing categories of connected fitness products, an opportunity that we believe has been permanently accelerated by the current COVID-19 crisis.It should be noted that the company faces significant risks going forward. These include new entrants, evolving consumer tastes as well as execution challenges. That being said, Terrys bullish thesis remains very much intact.Expounding on this, the analyst said, ... we believe that the window of opportunity for any meaningful competitor is rapidly closing, something that, along with the large and expanding addressable market for Pelotons high ARPU, high margin, extremely low churn subscription business, remains underappreciated by the market, even with the stocks recent outperformance.It should come as no surprise, then, that Terry stayed with the bulls. To this end, he kept a Buy rating and $138 price target on the stock. Investors could be pocketing a gain of 53%, should this target be met in the twelve months ahead. (To watch Terrys track record, click here)In general, other analysts are on the same page. PTONs Strong Buy consensus rating breaks down into 20 Buys, 2 Holds and 1 Sell. The $112.05 average price target brings the upside potential to 23%. (See PTON stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Originally posted here:
Cend Therapeutics Announces Acquisition of Impilo Therapeutics - Yahoo Finance

Deal value in the M&A market decreased in Sept 2020 compared to $35.7 bn in Aug 2020 – Express Pharma

In September 2020, the healthcare industry reported 84 deals worth $28.2 billion as compared to the last 12-month average (September 2019 to August 2020) of 75 deals worth $11.6 billion.

Deal value in the M&A market decreased in September 2020 compared to $35.7 billion in August 2020. Gilead Sciences to acquire Immunomedics, for $88.0 per share in cash, valuing the company at approximately $21 billion contributing 74 per cent of the total deal value during September 2020.

Other notable deals in the month are: Permira, a private equity firm to acquire Neuraxpharm Arzneimittel GmbH, a pharma company focused on the treatment of central nervous system disorders, for $1.8 billion; and Mylan N.V. to acquire the Intellectual Property and Commercialisation Rights of Aspen Pharmacare Holdings Limiteds Thrombosis Business in Europe, for $759 million.

Deal activity in pharma industry in September 2020

VC investments reported a marginal increase in deal value in September 2020

The healthcare industry reported 117 venture capital (VC) deals worth $3.7 billion in September 2020, compared to the last 12-month average (September 2019 to August 2020) of 117 deals worth $2.4 billion.

XtalPi Inc, a computation-driven biotech startup raising $318.8 million in series C round of financing to further develop its ID4 platform, in an attempt to build an AI-powered digital drug R&D infrastructure; Recursion Pharmaceuticals, raising $239.0 million in an oversubscribed series D financing to support the clinical development of its therapeutic pipeline; and InventisBio, a clinical-stage biotech company raising $147 million in Series D financing to support its current products into phase II clinical studies in China and the US, including D-0502 trials in hormone receptor-positive breast cancer and D-0120 trials in gout are the major VC deals reported in September 2020.

Go here to read the rest:
Deal value in the M&A market decreased in Sept 2020 compared to $35.7 bn in Aug 2020 - Express Pharma

Nanorobots Market 2020: Applications, Types and Growing Trends in Market, Gross – News by aeresearch

Business Internet Service Market 2020: Industry Size & Share, Business Strategies, Growth Analysis, Regional Demand By 2025 By Market Study Report

The report published on Business Internet Service Market is an invaluable foundation of insightful data helpful for the decision-makers to form the business strategies related to R&D investment, sales and growth, key trends, technological advan...

The Logistic Software report provides independent information about the Logistic Software industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challeng...

The research study 360 Degree Feedback Software market 2020 provides the detailed analysis of the current market status, investment plans, production and consumption, price trends, and analysis by market player, by region, by type, by application e...

The research study APP Store Monetisation market 2020 provides the detailed analysis of the current market status, investment plans, production and consumption, price trends, and analysis by market player, by region, by type, by application etc, an...

The Pumps and Motors report provides independent information about the Pumps and Motors industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges...

Go here to see the original:
Nanorobots Market 2020: Applications, Types and Growing Trends in Market, Gross - News by aeresearch

Nanotech opens up job options in variety of industries – BL on Campus

The word nano refers to the length scale (one nanometre is one-billionth of a metre) that is one thousand times smaller than the micro scale, the scale that was traditionally associated with the electronics industry. Viruses and DNA are examples of natural objects on the nano scale; in contrast a human cell can appear enormous.

The term nanotechnology refers to the engineering, measurement and understanding of nano-scaled materials and devices. Manipulating matter atom by atom and creating features on the atomic or nano scale is now a proven technology and there is an ever growing catalogue that utilises nanotechnology.

Nanotechnology represents an entire scientific and engineering field, broadly within Materials Science and Engineering, and not just a single product or even group of products. As a consequence of this there are several different types of nanotechnology, and many applications associated with each type. There are also several other types of nano-sized objects which exist in our environment, both natural and unnatural such as films and coatings, embedded nanotechnology, biologically natural, biological nanotechnology, natural particles, manufactured particles, nano-electrical mechanical systems.

Building on current nanotechnology-enabled applications in areas as diverse as consumer electronics, medicine, energy, water purification, aerospace, automotive, infrastructure, sporting goods, textiles, and agriculture, the nanotechnology research underway today will enable entirely new capabilities and products. Nanotechnology also underpins key industries of the future. For example, new architecture and paradigms exploiting nanotechnology are providing the foundation for artificial intelligence (AI), quantum information science (QIS), next-generation wireless communications, and advanced manufacturing.

While advances in modern electronics have long been at the nanoscale, new nanomaterials and designs will ensure the continued strength of the semiconductor industry, which powers computing, e-commerce, and national security. Nanotechnology also enables the rapid genomic sequencing and sensing required to advance medicine and biotechnology. Nanotechnology R&D has enabled early detection of emerging diseases and will lead to the treatments of the future. Past investments in nanotechnology research and development have provided a foundation to support the response to the Covid-19 pandemic. Nanotechnology-enabled applications include vaccines, sensors, masks, filters, and antimicrobial coatings.

Examples of nanotechnology innovations are: a highly sensitive wearable gas sensor; nanoparticles absorbed by plants to deliver nutrients; durable, conductive yarns made with MXene; electrodes that incorporate nanoparticles and enable the conversion of sunlight to hydrogen fuel; nano-engineered pores in a membrane for water filtration; drug-loaded nano particles carried by red blood cells; and the first programmable memristor computer, enabling low-power AI applications. Nanotechnology advances are impacting a variety of other sectors including consumer electronics, aerospace, automotive, infrastructure, sporting goods, and agriculture.

Research Infrastructure

The research infrastructure, including physical and cyber resources as well as education and workforce development efforts, is critical to support the entire funding ecosystem (National Nanotechnology Initiative), and agencies will continue to invest in these important areas. Agencies use a wide variety of mechanisms to support the research infrastructure, including Centre grants, instrumentation development or acquisition programmes, training grants, fellowships, and collaborative programmes that support workforce development.

Career opportunities

The scope and application of nanotechnology is tremendous. Indian engineering and science graduates are increasingly opting for nanotechnology. Right from medicine, pharmaceuticals, information technology, electronic, opto-electronics, energy, chemicals, advanced materials to textiles, nanotechnology has its applications. Nanotechnology provides job opportunities in health industry; pharmaceutical industry; agriculture industry; environment industry; food and beverage industry as well in government and private research institutes.

Skills

One needs to have a diehard passion for research, especially to find out new structures in the field of nanotechnology. It is important to have sound analytical skills, along with a scientific bent of mind. Analysing and interpreting skills are a necessity in this field and also to accept failures in experiments as a challenge. Other necessary skills which are required are: Good mathematical and computer programming skills; adequate laboratory training for expert handling of advanced equipment; ability to learn and adopt new techniques; have a systematic way of working; a natural propensity for research work; keep track of the latest scientific news, books and research magazines; a good background of physics, chemistry, medicine, electronics and biotechnology

Job Prospects

A lot of job opportunities and a research career exists in the areas of nano-device, nano-packaging, nano-wires, nano-tools, nano-biotechnology, nano-crystalline materials, nano-photonics and nano-porous materials to name a few. It is estimated that around three million nanotechnology skilled workforce will be required worldwide by 2021. Many government institutes and Indian industries have focused on nano-materials. It is also estimated nano-technology will create another five million jobs worldwide in support fields and industries. A professional in the field of nanotechnology can easily find lucrative jobs in most of fields.

Since nanotechnology is a special branch that essentially combines physics, chemistry, biology, engineering and technology, it is opening up job prospects for students specialising in these subjects. The career opportunities in the fields of nanoscale science and technology are expanding rapidly, as these fields have increasing impact on many aspects of our daily lives.

A professional in the field of nanotechnology can easily find viable career opportunities in various sectors. They can work in the field of nano-medicine, bio-informatics, stem cell development, pharmaceutical companies, and nano toxicology and nano power generating sectors.

The major areas for the development of applications involving nanotechnology are medical and pharmaceuticals, information technology, electronics, magnetics and opto-electronics, energy chemicals, advanced materials and textiles.

Nanotechnology has varied applications in drug delivery to treat cancer tumours (without using radiotherapy and chemotherapy), solar energy, batteries, display technologies, opto-electronic devices, semiconductor devices, biosensors, luminous paints, and many others. A major challenge in this emerging field is the training for a new generation of skilled professionals.

An abundance of job opportunities awaits candidates with an MTech in Nanotechnology from India and abroad. Indian industry has focused on nanomaterials and many scientific institutions have started research and development activities in the field. The CSIR has set up 38 laboratories, across the country, to carry out research and development work in this field. Those with a PhD in Nanotechnology will have vibrant opportunities in the R&D sectors.

It is a perfect career for those who have a scientific bent of mind and a passion for studying and experimenting with the minutest molecules. Students with a science and engineering background and even mathematics with a physics background can pursue Nanotechnology as a career. Candidates with MTech in Nanotechnology are in great demand both in India and abroad.

(The writer is Associate Professor, Department of Physics and Nanotechnology, SRM University)

Go here to see the original:
Nanotech opens up job options in variety of industries - BL on Campus

Predictions 2022: Year of personalisation of healthcare and therapies – Fortune India

What could change in the next 5 years? 2022 is the foundation year for an unprecedented amount of collaborative research and innovation. As we move ahead, an integrated healthcare industry will create new ways to diagnose patients; prevention will actually become the cure; and technology will provide unprecedented levels of patient information, making it easier than ever before to find therapies to treat individual-specific conditions, or even specific individuals.

In the next decade, global healthcare will blur the lines between different segments, and even sectors. The traditional distinction between different parts of the healthcare industry clinical practice, diagnostics, devices and pharmaceuticals has already begun to disappear. So will the barriers between innovators, service providers and technologists.

Digital health is already changing the face of diagnosis and drug discovery. In the future, new healthcare platforms will provide remote care to patients, smart sensors will monitor body chemistry and vital signs, and identify potential disease risk. Manufacturing technology will be increasingly refined and complex but not complicated.

That artificial intelligence (AI) and machine learning (ML) will accelerate along the spectrum of healthcare is a given. Robotics and virtual reality have already begun and will continue to aid doctors in the operation theatre to conduct surgery with much higher precision. Sensors monitoring vital signs, triggering alerts and even treatment are already making their mark.

Go here to see the original:
Predictions 2022: Year of personalisation of healthcare and therapies - Fortune India

Great news! Potential COVID-19 drug to mitigate the consequences of coronavirus infection identified – The Financial Express

There is also a possibility that the project could get a three-year renewal.

Coronavirus treatment: New drug to mitigate or prevent coronavirus infection may have been found! Researchers from the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have been making progress in the identification of new therapies that can be implemented rapidly and can combat COVID-19. They have now found a potential drug to prevent or mitigate the consequences of an infection caused by SARS-CoV-2, the novel coronavirus that has caused a global pandemic. The first results of the study have been published in Cytokine and Growth Factors Review journal and have been accessed by Financial Express Online.

The research is being led by principal researchers Fabiana Csukasi and Ivn Durn, and over the coming year, the team would be studying the impact of 4-Phenylbutiric acid (4-PBA) treatment in modulating the inflammatory response that is produced in severe COVID-19 cases. This inflammatory response can lead to excessive and uncontrolled release of cytokines, which are the molecules responsible for the organisation of the bodys defence. This uncontrolled release can cause severe reactions, going as far as triggering vascular hyperpermeability and muti-organ failure. The researchers have proposed controlling this cytokine storm through the help of the infected cells.

Durn said that when the cells are under stress due to the infection, they trigger the release of cytokines, and as the stress level increases, the call for cytokine also increases, leading to this storm. Therefore, Durn said that one possible treatment for this is reducing the stress on cells.

The researcher added that repurposing of 4-PBA, an anti-stress drug, could help in modulating the cellular stress. The drug has been approved for clinical usage in other diseases, and therefore, it should not be hard to apply for repurposing it in terms of COVID-19. Another important point to note is that cellular stress is also present in cases of aging, carcinogenesis or diabetes, all of which are comorbidities flagged as risk factors for COVID-19.

Durn said that the preliminary research was conducted on animal models and the results from the study have shown that mortality caused by cellular stress-induced respiratory failure was completely curbed by 4-PBA. The researcher added that the results also helped in the identification of Binding Immunoglobulin Protein (BiP), a marker of stress blood, as an indicator of situations of cellular stress. This could be explored and measured in affected patients.

The UMA professor said that this could mean that BiP levels could determine the efficacy of 4-PBA treatment as well as be an early indicator of the COVID-19 risk groups. Thus, it could help in the establishment of a correlation between high stress levels and the severity of the inflammation after the infection.

The researcher added that people with comorbidities have cellular stress in the first place, and an infection of coronavirus could make them more prone to fall severely ill or even die. Thus, if the status of a patients cellular stress became known, then healthcare workers would be able to detect their susceptibility before they get infected and also know how to treat them in time.

The study has been financed by the Government of Andalusias COVID-19 Fund and the initial grant has been to the tune of EUR 90,000. There is also a possibility that the project could get a three-year renewal.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know markets Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

More:
Great news! Potential COVID-19 drug to mitigate the consequences of coronavirus infection identified - The Financial Express

A copper-infused COVID-19 mask is making its way out of a WVU lab – Times-West Virginian

MORGANTOWN Whether behind the hotel front desk or the restaurant counter, hospitality and customer service employees come face-to-face with guests from all walks of life for hours on end.

With the delta variant on the rise and an upswing in COVID-19 cases, the hospitality business faces the challenge of staffing positions as people weigh their personal safety against their employment as the pandemic rages on.

Masking up remains one safe precaution.

But its also an uncomfortable gesture, as some masks may inflict wear and tear on the face or not provide an adequate level of protection for the worker, explained Ajay Aluri, founding director of the Hospitality Innovation and Technology Lab at West Virginia University.

As a native of India, where copper is king and touted for its antimicrobial properties, Aluri thought, Why not make a safer, more comfortable mask infused with copper when using for a longer period of time?

Copper has a special place in the culture and tradition of India, said Aluri, also associate professor of hospitality and tourism management in the Chambers College of Business and Economics. People wear copper bracelets and use copper utensils for cooking. And theres a notion, from the COVID standpoint, that copper is antimicrobial.

From the HIT Lab was born Hygenmask, a three-layered facemask containing a copper-infused nano-coated fabric, a sustainable bamboo fabric and an ePTFE (a biomaterial) filter. Wearers also dont have to worry about elf ears since the masks lack ear loops. Elastic head loops go over the head and can be tightened for a customized fit.

WVU HIT Lab is a platform for both industry and academia to come together to solve the problems of the hospitality and tourism industry. Before Hygenmask, Aluri and his students created Hygenkey, a copper touch tool with antiviral and antibacterial qualities, in response to the pandemic in 2020.

The mask is ideally for people who are always at the front desk or talking to people six to eight hours at a time, whether in restaurants, resorts, airports, or any hospitality and tourism industry, Aluri said. Some of these masks out there, if you wear them for a long time, it can be really rough on your skin. So we strived to make it more hygienic and sustainable from a fabric standpoint.

One of Aluris partners recommended a sustainable bamboo fabric, which offers a smooth feel but still fits tight around the face, he said.

But you dont have to take his word for it. Aluri reached across campus to ask scientists with the WVU School of Medicines Center for Inhalation Toxicology (iTOX) to test the product. Since the onset of the pandemic, the Center has been at the forefront of testing all sorts of masks from N95 alternatives to WVU gaiters to the Singers Mask to double masks.

The Center found that Aluris mask blocked up to 93% of droplets being respired.

The Hygenmask offers good protection to its users, said Timothy R. Nurkiewicz, director of the Center and E.J. Van Liere Endowed Professor and chair of the Department of Physiology and Pharmacology. Combined with physical distancing, good HVAC, limiting time in a crowd and limiting the crowd size, the mask should afford the users some confidence.

Researchers conducted fit testing, which evaluates how well a mask protects the person wearing the mask. A score of 100 is necessary to pass a N95 mask. Gaiters and saggy disposable masks typically score a one.

Aluris mask ranged from six-to -15 on the study participants.

Those numbers are substantially better than what you would find with your average cloth masks, which usually gets a fit factor of two, said Karen Woodfork, a teaching associate professor in the Department of Physiology and Pharmacology who was part of the research team.

People send us all kinds of masks and most of them get ones or twos, Nurkiewicz said. When we saw Ajays mask scoring in that range, that tells you theres a bit of protection there.

Nurkiewiczs lab did not test the copper properties of the mask.

Perhaps theres no better way to test a product than actually using it.

Aluri donned the mask during a 14-hour flight to India.

Im only taking it down when Im eating or drinking, Aluri said. I had no marks on my face and Hygenmask was quite comfortable.

Most of all, Nurkiewicz and his team believe that Aluris mask accomplishes its purpose and will be of benefit to its target audience those who serve the public day-to-day.

The mask sits away from your mouth enough so you can articulate better, Nurkiewicz said. Also, in terms of regular breathing, you will labor more with a mask that sits right on your lips. Theres some space there, making it more comfortable and making the wearer more likely to keep it on for a longer period of time.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Read more here:
A copper-infused COVID-19 mask is making its way out of a WVU lab - Times-West Virginian